What's Going On With Reneo Pharmaceuticals Stock Today?
What's Going On With Reneo Pharmaceuticals Stock Today?
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares initially traded higher Monday before turning negative after the company announced a proposed merger with OnKure, Inc.
Reneo Pharmicals, Inc.（納斯達克股票代碼：RPHM）的股價最初在週一上漲，然後在該公司宣佈擬議與OnKure, Inc.進行合併後轉爲負值。
The Details: Reneo and Onkure announced Monday that they have entered into a definitive merger agreement to combine the two companies in an all-stock transaction.
詳情：Reneo和Onkure週一宣佈，他們已簽訂最終合併協議，將兩家公司合併爲全股交易。
The resulting company, expected to operate as OnKure Therapeutics, will focus on advancing OnKure's products targeting oncogenic mutations in phosphoinositide 3-kinase alpha. This includes OnKure's lead program OKI-219.
由此產生的公司預計將以OnKure Therapeutics的名義運營，將專注於推進OnKure針對磷酸肌苷3激酶α致癌突變的產品。這包括 OnKure 的主導項目 OKI-219。
"OnKure has an experienced team of drug developers, and we are excited about the potential for OKI-219 to become a meaningful treatment option for patients suffering from breast cancer," said Mike Grey, executive chairman of Reneo Pharmaceuticals.
Reneo Pharmicals執行董事長邁克·格雷表示：“OnKure擁有一支經驗豐富的藥物開發團隊，我們對OKI-219 有可能成爲乳腺癌患者有意義的治療選擇感到興奮。”
In connection with the agreement, Reneo Pharmaceutics has entered into a subscription agreement for $65 million in private investment in public equity (PIPE) with a group of institutional investors, including Acorn Bioventures, Cormorant Asset Management, Deep Track Capital, Perceptive Advisors, Samsara BioCapital, Surveyor Capital and Vestal Point Capital.
根據該協議，Reneo Pharmaceutics已與包括Acorn Bioventures、Cormorant Asset Management、Deep Track Capital、Perceptive Advisors、Samsara BioCapital、Surveyor Capital和Vestal Point Capital在內的一批機構投資者簽訂了6500萬美元的公募股權私人投資（PIPE）的認購協議。
Including PIPE proceeds, the combined company is expected to hold about $120 million of cash, cash equivalents and short terms investments at closing.
包括PIPE收益在內，合併後的公司預計將在收盤時持有約1.2億美元的現金、現金等價物和短期投資。
Pre-merger Reneo stockholders are anticipated to hold about 31% of the combined company's shares, while pre-merger OnKure stockholders are expected to own approximately 69%.
合併前的Reneo股東預計將持有合併後公司約31％的股份，而合併前的OnKure股東預計將擁有約69％的股份。
The merger and PIPE agreement are subject to approval by stockholders of both companies, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission and the condition that Reneo Pharmaceuticals has at least $55 million in net cash excluding the PIPE agreement. The transactions are expected to close later this year.
合併和PIPE協議須經兩家公司股東的批准，向美國證券交易委員會提交的註冊聲明的有效性，以及不包括PIPE協議在內的Reneo Pharmicals擁有至少5500萬美元的淨現金的條件。這些交易預計將於今年晚些時候完成。
Related Link: Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
相關鏈接：本月可能挽救您的投資組合的四大醫療保健股票
RPHM Price Action: Reneo Pharmaceuticals shares were down 10.8% at $1.61 at the time of writing, according to Benzinga Pro.
RPHM價格走勢：根據Benzinga Pro的數據，在撰寫本文時，Reneo Pharmicals的股價下跌了10.8％，至1.61美元。
Image: 385506 from Pixabay.
圖片：來自 Pixabay 的 385506。